ANDOVER, Mass., Feb. 21, 2023 (GLOBE NEWSWIRE) -- TransMedics Group, Inc. (“TransMedics”) (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today announced the company will be participating in two upcoming investor conferences. TransMedics management is scheduled to participate in a fireside chat at the Cowen 43rd Annual Healthcare Conference in Boston on Monday, March 6, 2023, at 9:10 a.m. EST and to present virtually at the Oppenheimer 33rd Annual Healthcare Conference on Monday, March 13, 2023, at 12:00 p.m. EST.
Event: Cowen 43rd Annual Healthcare Conference
Date: Monday, March 6, 2023
Time: 9:10 a.m. EST
Event: Oppenheimer 33rd Annual Healthcare Conference
Date: Monday, March 13, 2022
Time: 12:00 p.m. EST
A live and archived webcast of the presentations will be available on the “Investors” section of the TransMedics website at https://investors.transmedics.com/.
About TransMedics Group, Inc.
TransMedics is the world’s leader in portable extracorporeal warm perfusion and assessment of donor organs for transplantation. Headquartered in Andover, Massachusetts, the company was founded to address the unmet need for more and better organs for transplantation and has developed technologies to preserve organ quality, assess organ viability prior to transplant, and potentially increase the utilization of donor organs for the treatment of end-stage heart, lung, and liver failure.
Investor Contact:
Brian Johnston
332-895-3222
This email address is being protected from spambots. You need JavaScript enabled to view it.
| Last Trade: | US$83.31 |
| Daily Change: | -5.19 -5.86 |
| Daily Volume: | 3,527,560 |
| Market Cap: | US$2.780B |
October 28, 2024 April 30, 2024 February 28, 2024 | |
C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MORE
Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MORE
